Nuveen
IKT icon

Nuveen’s Inhibikase Therapeutics IKT Stock Holding History

Nuveen’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$864K Sell
425,492
-46,907
-10% -$84K ﹤0.01% 3009
2026
Q1 		$794K Buy
472,399
+393,740
+501% +$699K ﹤0.01% 2676
2025
Q4 		$161K Hold
78,659
– – ﹤0.01% 3179
2025
Q3 		$127K Hold
78,659
– – ﹤0.01% 3211
2025
Q2 		$153K Buy
+78,659
New +$154K ﹤0.01% 3207

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's IKT Position: Q2 2026 in Review

Nuveen reduced its Inhibikase Therapeutics (IKT) stake by 9.9% in Q2 2026, selling an estimated $84K and leaving 425,492 shares worth $864K. The position accounts for ﹤0.01% of the portfolio, ranked #3009.

Nuveen first reported a position in IKT in Q2 2025 and has held it in 5 quarters since. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Nuveen held 425,492 shares of Inhibikase Therapeutics worth $864K as of Q2 2026.
  • Nuveen sold 46,907 Inhibikase Therapeutics shares in Q2 2026, an estimated $84K.
  • Inhibikase Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3009 holding.
  • Nuveen first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.